![](/images/png/glyphicons-368-expand.png)
![](/images/png/glyphicons-791-one-day.png)
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Justin Kim Downgraded (ALDX) to Hold on, Oct 17th, 2023
Justin Kim of Oppenheimer, Downgraded "Aldeyra Therapeutics, Inc." (ALDX) to Hold on, Oct 17th, 2023.
Justin has made no other calls on ALDX in the last 4 months.
There is 1 other peer that has a rating on ALDX. Out of the 1 peers that are also analyzing ALDX, 0 agree with Justin's Rating of Hold.
This is the rating of the analyst that currently disagrees with Justin
- Matthew Caufield of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $15 on, Friday, June 30th, 2023
Contributing Sources